$ARCT
Arcturus Therapeutics Holdings Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024055702 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $49.86M $38.01M
YoY Change 373.99% -52.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.32M $14.85M
YoY Change -6.87% 7.91%
% of Gross Profit
Research & Development $58.67M $53.57M
YoY Change 11.39% 3.49%
% of Gross Profit
Depreciation & Amortization $909.0K $904.0K
YoY Change 23.34% 56.4%
% of Gross Profit
Operating Expenses $70.99M $68.42M
YoY Change 7.73% 4.42%
Operating Profit -$21.13M -$30.41M
YoY Change -61.85% -306.11%
Interest Expense $3.760M $3.963M
YoY Change 10.56% 84.41%
% of Operating Profit
Other Income/Expense, Net $4.148M $4.016M
YoY Change 27.55% 62.13%
Pretax Income -$17.37M -$26.45M
YoY Change -66.59% -152.01%
Income Tax -$200.0K $400.0K
% Of Pretax Income
Net Earnings -$17.22M -$26.82M
YoY Change -67.24% -152.84%
Net Earnings / Revenue -34.53% -70.55%
Basic Earnings Per Share -$0.64 -$1.00
Diluted Earnings Per Share -$0.64 -$1.00
COMMON SHARES
Basic Shares Outstanding 26.93M 26.92M
Diluted Shares Outstanding 26.97M 26.88M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $260.3M $288.4M
YoY Change -19.52% -12.06%
Cash & Equivalents $260.3M $288.4M
Short-Term Investments
Other Short-Term Assets $62.59M $60.34M
YoY Change 6.14% 1358.42%
Inventory
Prepaid Expenses
Receivables $24.09M $27.06M
Other Receivables $0.00 $0.00
Total Short-Term Assets $347.0M $375.8M
YoY Change -9.93% -11.49%
LONG-TERM ASSETS
Property, Plant & Equipment $11.18M $11.76M
YoY Change -74.16% -6.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.885M $1.885M
YoY Change -11.38% -10.92%
Total Long-Term Assets $41.60M $43.06M
YoY Change -8.37% -7.01%
TOTAL ASSETS
Total Short-Term Assets $347.0M $375.8M
Total Long-Term Assets $41.60M $43.06M
Total Assets $388.6M $418.8M
YoY Change -9.76% -11.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.91M $9.144M
YoY Change 2.1% -52.73%
Accrued Expenses $35.45M $34.77M
YoY Change 23.25% 7.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $91.72M $115.4M
YoY Change 1.52% 28.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $38.31M $39.45M
YoY Change -30.51% 2181.49%
Total Long-Term Liabilities $38.31M $39.45M
YoY Change -30.51% 2181.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $91.72M $115.4M
Total Long-Term Liabilities $38.31M $39.45M
Total Liabilities $130.0M $154.9M
YoY Change -10.62% 9.36%
SHAREHOLDERS EQUITY
Retained Earnings -$411.9M -$394.7M
YoY Change 21.18% 37.33%
Common Stock $27.00K $27.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $258.6M $264.0M
YoY Change
Total Liabilities & Shareholders Equity $388.6M $418.8M
YoY Change -9.76% -11.05%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$17.22M -$26.82M
YoY Change -67.24% -152.84%
Depreciation, Depletion And Amortization $909.0K $904.0K
YoY Change 23.34% 56.4%
Cash From Operating Activities -$30.14M -$5.557M
YoY Change -159.33% -84.51%
INVESTING ACTIVITIES
Capital Expenditures $328.0K $240.0K
YoY Change -7.34% -65.27%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$328.0K -$240.0K
YoY Change -7.34% -65.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.403M 2.188M
YoY Change 2456.38% -108.0%
NET CHANGE
Cash From Operating Activities -30.14M -5.557M
Cash From Investing Activities -328.0K -240.0K
Cash From Financing Activities 2.403M 2.188M
Net Change In Cash -28.07M -3.609M
YoY Change -155.53% -94.35%
FREE CASH FLOW
Cash From Operating Activities -$30.14M -$5.557M
Capital Expenditures $328.0K $240.0K
Free Cash Flow -$30.47M -$5.797M
YoY Change -160.39% -84.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001768224
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38942
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
ARCTURUS THERAPEUTICS HOLDINGS INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0595345
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
10628 Science Center Drive
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
900-2660
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
ARCT
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26931826
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
288396000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292005000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
55000000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
55000000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27057000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32064000
CY2024Q1 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
5335000
CY2023Q4 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
7521000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
375788000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
386590000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11763000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12427000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29413000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28500000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2024Q1 us-gaap Assets
Assets
418849000
CY2023Q4 us-gaap Assets
Assets
429402000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9144000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5279000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34770000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31881000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
71516000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
44829000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
115430000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
81989000
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11795000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
42496000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27652000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25907000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
497000
CY2024Q1 us-gaap Liabilities
Liabilities
154877000
CY2023Q4 us-gaap Liabilities
Liabilities
150889000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26917000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26917000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26828000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26828000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
27000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
658628000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
646352000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394683000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367866000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
263972000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
278513000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
418849000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
429402000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38012000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80285000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53573000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51768000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14851000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13762000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
68424000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
65530000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30412000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
14755000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-53000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-328000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4016000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2477000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26449000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
50857000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
368000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
103000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26817000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
50754000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.87
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26879000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26555000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26879000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27149000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26817000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
50754000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26817000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
50754000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
278513000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26817000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10088000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2188000
CY2024Q1 arct Non Cash Asset Disposal
NonCashAssetDisposal
473000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2736000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
263972000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270312000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
50754000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8182000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
329248000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26817000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
50754000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
904000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
578000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10088000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8182000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-53000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-160000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-502000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5007000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
89719000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2186000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4549000
CY2024Q1 arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-1823000
CY2023Q1 arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-988000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3865000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11788000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2339000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
986000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4014000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
10343000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-991000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1029000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5557000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35871000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
240000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
691000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-240000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-691000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2188000
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
27364000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2188000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-27364000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3609000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-63926000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348890000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393977000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
345281000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330051000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
2102000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
107000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394700000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367900000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
345300000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
327935000
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
55000000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2116000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
345281000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330051000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1900000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2100000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
288396000
CY2024Q1 us-gaap Dividends
Dividends
0
CY2023Q1 us-gaap Dividends
Dividends
0
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
32064000
CY2024Q1 arct Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
34068000
CY2024Q1 arct Contract With Customer Asset Deductions
ContractWithCustomerAssetDeductions
39075000
CY2024Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
27057000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
87325000
CY2024Q1 arct Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
33998000
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
38012000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
83311000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20934000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21167000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9171000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8740000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11763000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12427000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7102000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5918000
CY2024Q1 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
7649000
CY2023Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
7633000
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
979000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
641000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4270000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4309000
CY2024Q1 arct Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
1234000
CY2023Q4 arct Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
2333000
CY2024Q1 arct Vinbiocare Contractual Liabilities
VinbiocareContractualLiabilities
2993000
CY2023Q4 arct Vinbiocare Contractual Liabilities
VinbiocareContractualLiabilities
2514000
CY2024Q1 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
10543000
CY2023Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
8533000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34770000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31881000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1400000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5200000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10088000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8182000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4257000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5019000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5274000
CY2024Q1 arct Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
23703000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38253000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6331000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
31922000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.048
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000

Files In Submission

Name View Source Status
arct-20240331_htm.xml Edgar Link completed
0000950170-24-055702-index-headers.html Edgar Link pending
0000950170-24-055702-index.html Edgar Link pending
0000950170-24-055702.txt Edgar Link pending
0000950170-24-055702-xbrl.zip Edgar Link pending
arct-20240331.htm Edgar Link pending
arct-20240331.xsd Edgar Link pending
arct-ex10_33.htm Edgar Link pending
arct-ex31_1.htm Edgar Link pending
arct-ex31_2.htm Edgar Link pending
arct-ex32_1.htm Edgar Link pending
arct-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img267161004_0.jpg Edgar Link pending
img267161004_1.jpg Edgar Link pending
img267161004_2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending